Clinical Trials Browser

Phase 1/2 × ON 01910 × Thoracic × Clear all

NCT04263090 2024-05-09

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Phase 1/2 Completed

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis